Go online to PeerView.com/GRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma according to transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.